Ten years ago, Victoria Hale wrote a manifesto targeting five diseases in need of drug development and turned it into a business plan for the first pharmaceutical not-for-profit in the United States. Today, her organization, the Institute for OneWorld Health, is on the verge of proving that its no-profit/no-loss model can work. Its first drug, paromomycin — a treatment for visceral leishmaniasis, an illness spread by sand flies that mostly afflicts the poorest of the poor — is months from completing its final stage of clinical trials. Up next: malaria. Backed by a $42.6 million grant from the Gates Foundation, OneWorld Health aims to create and market semisynthetic artemisinin, a key malaria-fighting ingredient that’s in short supply.JV
collectionsNewslettersInnovation FestivalCurrent Issue
World Changing Ideas
New workplaces, new food sources, new medicine--even an entirely new economic system.
The major tech ecosystems that battle for our attention and dollars.
What’s next for hardware, software, and services.
The brave new world of automation, from AI to drones.
How our urban centers are building toward the future.
Most Creative People
See members of our Most Creative People in Business community: leaders who are shaping the future of business in creative ways.
An award-winning team of journalists, designers, and videographers who tell brand stories through Fast Company's distinctive lens.